8-K: Pulse Biosciences Announces Financial Results and $60 Million Rights Offering

Pulse Biosciences reported its 2023 financial results and announced a rights offering to raise up to $60 million.

Summary

• Pulse Biosciences announced its financial results for the fourth quarter and full year ended December 31, 2023.
• The company's total GAAP costs and expenses for the full year 2023 were $43.6 million, a decrease from $58.8 million in 2022.
• The GAAP net loss for the full year 2023 was $42.2 million, compared to a $58.5 million loss in 2022.
• Cash and cash equivalents totaled $44.4 million as of December 31, 2023, down from $61.1 million at the end of 2022.
• Pulse Biosciences plans to initiate a rights offering to existing stockholders to raise up to $60 million.
• The rights offering will be for units consisting of one share of common stock and warrants to purchase one additional share.
• The subscription price per unit will be the lesser of $10.00 or the volume weighted average price of the stock over the 10 trading days prior to the offering's expiration.
• The company also filed a preliminary registration statement for a universal shelf offering of up to $50 million over three years.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive developments in product development and clinical trials, the company's financial performance is weak, and a significant capital raise is needed. The sentiment is neutral to slightly negative due to the financial challenges.

Positives

• The company achieved FDA clearance for its CellFX nsPFA Percutaneous Electrode.
• Clinical trial data for thyroid nodules and cardiac catheter showed promising results.
• The company reduced its full year GAAP costs and expenses to $43.6 million in 2023 from $58.8 million in 2022.
• The full year GAAP net loss improved to $42.2 million in 2023 from $58.5 million in 2022.
• The rights offering is supported by the company's Executive Chairman and majority stockholder.

Negatives

• The company experienced a GAAP net loss of $42.2 million for the full year 2023.
• Cash and cash equivalents decreased from $61.1 million at the end of 2022 to $44.4 million at the end of 2023.
• The company's total revenue for 2023 was $0, down from $700,000 in 2022.

Risks

• The company's future operations are dependent on successful fundraising efforts.
• The rights offering is subject to SEC approval and market conditions.
• The company's technology is still in development and may not achieve commercial success.
• The company is reliant on the success of its CellFX nsPFA technology.
• The company has a history of losses and may not achieve profitability.

Future Outlook

The company plans to continue developing its CellFX nsPFA technology and seek commercialization, while also pursuing additional funding through the rights offering and universal shelf registration.

Management Comments

• Kevin Danahy, President and Chief Executive Officer, stated that the team executed on the development of the CellFX nsPFA devices in 2023.
• Kevin Danahy highlighted significant milestones such as the FDA clearance of the CellFX nsPFA Percutaneous Electrode System and positive clinical results.
• Robert Duggan, the company's Executive Chairman, has indicated his support for the rights offering and his intent to participate.

Industry Context

Pulse Biosciences is operating in the bioelectric medicine space, focusing on non-thermal tissue ablation. The company's technology is aimed at addressing conditions like atrial fibrillation, which is a significant market with existing treatment options. The company is competing with other medical device companies in the ablation space.

Comparison to Industry Standards

• Pulse Biosciences is developing a novel nsPFA technology, which is different from traditional thermal ablation methods used by companies like Medtronic and Boston Scientific.
• The company's focus on non-thermal ablation is a differentiating factor compared to companies using radiofrequency or cryoablation.
• The clinical results presented for the CellFX nsPFA 360 Cardiac Catheter are promising, but further studies are needed to compare its efficacy and safety to existing catheter ablation technologies.
• The company's financial losses are typical for a development-stage medical device company, but the need for a rights offering indicates a need for additional capital to continue operations.

Stakeholder Impact

• Shareholders will have the opportunity to participate in the rights offering.
• Employees are impacted by the company's financial performance and restructuring efforts.
• Customers and patients may benefit from the company's technology if it achieves commercial success.
• Creditors are impacted by the company's financial health and ability to repay debts.

Next Steps

• The company will file a registration statement with the SEC for the rights offering.
• The company will announce the record date for the rights offering.
• The company will continue discussions with the FDA regarding the CellFX nsPFA Cardiac Clamp.
• The company will continue to develop and commercialize its CellFX nsPFA technology.

Key Dates

Keywords

Pulse Biosciences, CellFX, nsPFA, rights offering, FDA clearance, clinical trial, cardiac catheter, financial results, stock offering, bioelectric medicine